drugset / Trial / NCT00820911

Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

NCT00820911

Phase 2 Completed 175 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.

Timeline

Start
2008-09
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide
Subject sotrastaurin Small molecule 200 mg
Subject sotrastaurin Small molecule 300 mg
Background Everolimus Small molecule

Indications

No indication recorded.